539730.BO Stock Analysis
53
Avoid
Based on Eyestock quantitative analysis, 539730.BO`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Market cap $B
0.019
Dividend yield
0.08 %
Shares outstanding
4.72 B
Fredun Pharmaceuticals Ltd. engages in the manufacture and sale of pharmaceuticals, neutraceuticals, herbal and dietary supplements. The company is headquartered in Mumbai, Maharashtra and currently employs 260 full-time employees. The company went IPO on 2016-03-17. The firm is primarily engaged in the business of pharmaceuticals and healthcare. The firm operates through four segments: Generics (Exports & Fredun Gx), Pet Healthcare (Freossi), Nutraceuticals (Fredun Nutrition) and Cosmeceuticals (Bird and Beauty or BnB). The company offers a range of products, including antihypertensive, antidiabetic, antiretroviral drugs (ARVs) and narcotics. The company is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The firm primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.